Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2025)

Historic FCF Margin for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 127.77%.

  • ARS Pharmaceuticals' FCF Margin rose 5785700.0% to 127.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 60.25%, marking a year-over-year increase of 17322400.0%. This contributed to the annual value of 14.57% for FY2024, which is 1981512300.0% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported FCF Margin of 127.77% as of Q3 2025, which was up 5785700.0% from 288.61% recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' FCF Margin registered a high of 48.17% during Q4 2024, and its lowest value of 166990.0% during Q2 2023.
  • For the 4-year period, ARS Pharmaceuticals' FCF Margin averaged around 21702.52%, with its median value being 1047.66% (2022).
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -1654822400bps in 2023, then surged by 1655266000bps in 2024.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' FCF Margin stood at 3022.22% in 2022, then tumbled by -5425bps to 166990.0% in 2023, then soared by 100bps to 48.17% in 2024, then tumbled by -365bps to 127.77% in 2025.
  • Its last three reported values are 127.77% in Q3 2025, 288.61% for Q2 2025, and 512.14% during Q1 2025.